Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Metagenomi, Inc. Common Stock(MGX)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for MGX
11/02/2026: MGX (1-star) is currently NOT-A-BUY. Pass it for now.
Metagenomi, Inc. is a clinical-stage biotechnology company focused on developing proprietary gene-editing therapies using a unique, metagenomics-based discovery platform. The company's core strength lies in its extensive database of novel nucleases, which it leverages through internal programs and strategic partnerships with major pharmaceutical firms. Its primary investment story hinges on the potential for its gene-editing systems to address unmet medical needs in rare and genetic diseases. However, the company faces significant execution and competitive risks, as it currently lacks commercial products and operates in a capital-intensive, crowded field. The stock may suit growth-oriented investors with a high risk tolerance who are interested in the long-term potential of gene-editing technologies.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers high-growth potential in gene editing but carries significant clinical and commercial risk. |
| Momentum investor | Weak fit | This is a volatile, news-driven biotech stock that may not suit pure momentum strategies without sustained positive catalysts. |
| Value investor | Weak fit | The company is in an early, cash-burning stage and lacks the earnings or assets to justify a value-based investment thesis. |
| Dividend investor | Weak fit | There is no history or prospect of dividend payments as the firm focuses entirely on capital-intensive R&D. |
| Low-risk investor | Weak fit | Clinical-stage biotechnology stocks are inherently high-risk and inappropriate for conservative, capital-preservation portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Biotech stocks are highly sensitive to clinical trial outcomes and regulatory news. |
| Valuation risk | High | The company's valuation is based on future pipeline success rather than current earnings. |
| Competition risk (Biotech) | Medium / high | The gene editing field is crowded with well-funded competitors developing similar or superior technologies. |
| Business quality | Medium | While the platform is scientifically rigorous, the company is not yet a commercial, self-sustaining entity. |
| Dividend income | Low / none | This is a growth-stage biotech that does not provide income to shareholders. |
| Execution risk | High | Translating preclinical discoveries into approved human therapies is a complex and frequently unsuccessful process. |
Price Behavior
Steep Decline
The stock price has dropped sharply with strong downward pressure.
Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type Stock | Historic Profit -10.74% | Avg. Invested days 24 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/02/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 29.48M USD | Price to earnings Ratio - | 1Y Target Price 7 |
Price to earnings Ratio - | 1Y Target Price 7 | ||
Volume (30-day avg) 158.4K shares | Beta 0.7 | 52 Weeks Range 0.72 - 2.42 | Updated Date 11/01/2026 |
52 Weeks Range 0.72 - 2.42 | Updated Date 11/01/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.49 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Strategic Collaborations | Upfront payments, milestone payments, and potential royalties from partnerships with large pharmaceutical companies. | The company relies on major pharma partners to validate and help fund the development of its gene-editing tools. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -53.42M | Price to Sales(TTM) 2.17 |
Enterprise Value -53.42M | Price to Sales(TTM) 2.17 | ||
Enterprise Value to Revenue 0.71 | Enterprise Value to EBITDA - | Shares Outstanding 37.78M | Shares Floating 25.54M |
Shares Outstanding 37.78M | Shares Floating 25.54M | ||
Percent Insiders 19.02 | Percent Institutions 18.44 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.